CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity.

For detail information, see the CohBar's press release.

https://www.cohbar.com/news-media/press-releases/detail/143/cohbar-completes-enrollment-in-the-phase-1b-clinical-trial

CB4211 is a first-in-class mitochondria based therapeutic.  The peptide used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NAFLD Activty score in the STAM™ mouse model was presented at AASLD 2017.

For detailed information, see the AASLD 2017 poster.

https://d1io3yog0oux5.cloudfront.net/_5d5dcdc70c99e7f58b471e2c6fdcbb2c/cohbar/db/391/2665/pdf/Cundy+et+al+2017+AASLD+Liver+Meeting+Poster+%232010.pdf

In the future, we believe that further clinical trial results for CB4211 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.